Does tirzepatide burn visceral fat — and what does the evidence actually show?

What exactly is visceral fat, and why does burning it matter?

There is a common assumption that body fat is essentially uniform, that losing weight just means less of it everywhere, roughly equally. That is not quite right. The body stores fat in broadly two compartments: subcutaneous fat, which sits just beneath the skin, and visceral fat, which accumulates deep in the abdominal cavity around the liver, pancreas, intestines and other organs. The two behave differently at a cellular level. Visceral fat is more metabolically active, releasing inflammatory signals and free fatty acids directly into the portal circulation that feeds the liver. Higher visceral fat loads are associated with insulin resistance, type 2 diabetes, fatty liver, raised triglycerides and a greater risk of cardiovascular events, even in people whose overall weight appears moderate. This is why clinicians and researchers pay close attention not just to total body weight lost during treatment, but to where that weight comes from. A treatment that preferentially reduces visceral stores offers a different quality of metabolic benefit to one that trims subcutaneous fat alone. Our page on how Mounjaro affects visceral fat explores that question in detail, covering both the mechanism and what the clinical evidence shows. The tirzepatide overview on this site covers the broader mechanism in more detail, but the visceral-fat question specifically deserves its own answer, which is what this page provides.

What does the trial evidence say about tirzepatide and visceral fat reduction?

The SURMOUNT-1 trial, published in the New England Journal of Medicine, enrolled 2,539 adults with obesity or overweight plus at least one weight-related condition, without type 2 diabetes, and ran for 72 weeks. Participants on the 15mg dose achieved an average body-weight reduction of around 20 to 21 percent. Nested imaging substudies within the SURMOUNT programme went further than the scales: they used MRI and CT assessments to examine fat compartment changes specifically. Those analyses found that a disproportionate fraction of the fat lost came from visceral adipose tissue rather than subcutaneous stores. In practical terms, the reduction in visceral fat volume was proportionally greater than the overall percentage of weight lost. Researchers have attributed part of this to tirzepatide's dual receptor activity, it acts on both GLP-1 and GIP receptors, a combination that influences insulin sensitivity and energy metabolism in ways that single-agonist treatments do not fully replicate. How tirzepatide affects fat metabolism across different tissue types is an area where the evidence continues to develop. What the existing data already supports, however, is that the metabolic improvements seen in trials (including improvements to blood glucose, triglycerides and liver fat markers) are consistent with meaningful visceral fat reduction beyond what overall weight loss alone would predict.

Does this mean tirzepatide specifically targets visceral fat?

Not quite, and this distinction is worth sitting with rather than glossing over. Tirzepatide does not have a direct instruction to seek out visceral deposits and dissolve them. It works by reducing appetite, slowing gastric emptying and improving insulin signalling, which together create a sustained calorie deficit. Where the body draws from during that deficit depends on a mix of factors including hormonal environment, physical activity, genetics and baseline fat distribution. What the trial data shows is that, under those conditions, visceral fat tends to reduce proportionally more than subcutaneous fat in people using tirzepatide, not because the medicine hunts it, but because visceral adipose tissue is more metabolically responsive to the hormonal shifts tirzepatide produces. This is broadly consistent with what is seen when insulin resistance improves: the body's fat-mobilisation pattern shifts. The deeper look at how Mounjaro affects fat loss explores this mechanism further. NICE's appraisal of tirzepatide (TA1026) concludes that the weight reductions achieved are clinically meaningful and recommends its use in eligible adults, a judgement that factors in the metabolic, not just the cosmetic, dimension of fat loss.

Who is eligible, and what should you do next?

Tirzepatide, sold in the UK as Mounjaro, is licensed for adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition such as high blood pressure, raised cholesterol, type 2 diabetes or obstructive sleep apnoea. Lower BMI thresholds can apply for certain ethnic backgrounds under UK clinical guidance. Eligibility alone does not determine suitability, a prescriber will look at your medical history, current medicines and individual circumstances before recommending treatment. If you are thinking about the cost of Mounjaro as a private treatment, that page sets out what an honest price includes. For a prescription medicine, the clinical review matters far more than finding the lowest number. If you have questions about whether this treatment is right for your situation, speaking to our prescribers is the straightforward next step, no referral required, and consultations are free.